Bogart Wealth LLC Decreases Stake in Edwards Lifesciences Corporation (NYSE:EW)

Bogart Wealth LLC cut its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 98.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,040 shares of the medical research company's stock after selling 91,728 shares during the period. Bogart Wealth LLC's holdings in Edwards Lifesciences were worth $75,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Prosperity Consulting Group LLC increased its holdings in shares of Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares during the last quarter. Arlington Trust Co LLC boosted its stake in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after purchasing an additional 135 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after purchasing an additional 142 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the transaction, the vice president owned 33,496 shares in the company, valued at approximately $2,514,879.68. The trade was a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,848 shares of company stock valued at $2,314,488 in the last three months. Corporate insiders own 0.34% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EW shares. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Citigroup reaffirmed a "buy" rating and issued a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Evercore ISI upped their price objective on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $81.00.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $1.15 during mid-day trading on Wednesday, hitting $75.66. The company had a trading volume of 2,191,841 shares, compared to its average volume of 4,443,809. Edwards Lifesciences Corporation has a 52-week low of $58.93 and a 52-week high of $88.61. The stock's 50 day moving average price is $76.40 and its 200-day moving average price is $73.39. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The company has a market capitalization of $44.38 billion, a P/E ratio of 10.81, a P/E/G ratio of 3.93 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the firm earned $0.66 earnings per share. The company's quarterly revenue was up 6.2% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.